ReviewCurrent rheumatology reports2025
Axial Spondyloarthritis Clinical Research Year in Review: SPARTAN 2024 Annual Meeting Proceedings.
Review in Current rheumatology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical and MRI remission in axial spondyloarthritis: one-year outcomes and predictors from the TRACE treat-to-target study with secukinumab.Arthritis research & therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe purpose of this review is to highlight high impact clinical research in axial spondyloarthritis that was published between May 2023 and April 2024. These publications were presented at the SPARTAN annual meeting in May 2024. RECENT
findingsThree publications addressed the rate and predictors of radiographic progression in axial spondyloarthritis. MRI-based synthetic CT was introduced as a new modality to assess spinal structural damage. One of the first definitions of difficult to treat axial spondyloarthritis was published. Biologic taper, flare rates, and predictors of flares were discussed. Minimally invasive one-level osteotomy can be an option to correct kyphosis with less risk compared to standard approach. Different therapeutic classes seem to be protective against anterior uveitis in axial spondyloarthritis. Patients who receive biologic or targeted synthetic disease modifying antirheumatic drugs are at increased risk of non-serious infections, but not serious infections that are associated with hospitalization or mortality. This year-in-review session covered different concepts, including imaging and radiographic progression, difficult to treat axial spondyloarthritis, biologic taper, surgery, anterior uveitis, and risk of infections.
Indexed as
Identifiers
39754694What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.